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Background: We retrospectively report treatment results of our single-centre experience with hypofractionated
stereotactic radiotherapy (hfSRT) of limited brain metastases in primary and recurrence disease situations. Our aim
was to find the most effective and safe dose concept.
Methods: From 04/2006 to 12/2010, 75 patients, with 108 intracranial metastases, were treated with hfSRT.
52 newly diagnosed metastases (48%), without up-front whole brain radiotherapy (WBRT), received hfSRT as a
primary treatment. 56 metastases (52%) received a prior WBRT and were treated in this study in a recurrence
situation. Main fractionation concepts used for primary hfSRT were 6-7x5 Gy (61.5%) and 5x6 Gy (19.2%), for
recurrent hfSRT 7-10x4 Gy (33.9%) and 5-6x5 Gy (33.9%).
Results: Median overall survival (OS) of all patients summed up to 9.1 months, actuarial 6-and 12-month-OS was
59% and 35%, respectively. Median local brain control (LC) was 11.9 months, median distant brain control (DC) 3.9
months and intracranial control (IC) 3.4 months, respectively. Variables with significant influence on OS were Gross
Tumour Volume (GTV) (p = 0.019), the biological eqivalent dose (calculated on a 2 Gy single dose, EQD2, α/β = 10)
< and ≥ median of 39 Gy (p = 0.012), extracerebral activity of the primary tumour (p < 0.001) and the steroid
uptake during hfSRT (p = 0.03). LC was significantly influenced by the EQD2, ≤ and > 35 Gy (p = 0.004) in both
uni- and multivariate Cox regression analysis. Median LC was 14.9 months for EQD2 >35 Gy and 3.4 months for
doses ≤35 Gy, respectively. Early treatment related side effects were usually mild. Nevertheless, patients with a
EQD2 >35 Gy had higher rates of toxicity (31%) than ≤35 Gy (8.3%, p=0.026).
Conclusion: Comparing different dose concepts in hfSRT, a cumulative EQD2 of ≥35 Gy seems to be the most
effective concept in patients with primary or recurrent limited brain metastases. Despite higher rates of only mild
toxicity, this concept represents a safe treatment option.
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Cancer patients develop brain metastases in 10-40%
[1,2]. The aim of treatment is to provide disease control
with a good quality of life, even though prolonged sur-
vival may not always be achieved [3]. Whole brain radio-
therapy (WBRT) is considered to be the standard
treatment option for multiple brain filiae [4,5]. Concerns
about WBRT achieving only a limited treatment response* Correspondence: Steinmann.Diana@mh-hannover.de
Radiation Oncology, Medical School Hannover, Carl-Neuberg-Str. 1, Hannover
30625, Germany
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reproduction in any medium, provided the orand causing side-effects like cognitive and neurological
deficits, and reduced quality of life [6-10] lead us to focus
on options like stereotactic radiosurgery (SRS) or hypo-
fractionated stereotactic radiotherapy (hfSRT) in cases of
limited brain metastases. SRS is limited by the proximity
to critical brain regions, the lesions’ dimension and is
typically restricted to tumours ≤3 cm diameter (15 ccm)
[11]. Large metastases and irregular contrast enhance-
ment have been shown to correlate with an inferior out-
come after SRS [12,13] or enhanced side effects [14,15].
Different study groups used hfSRT in order to overcomel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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providing radiobiological advantages [16-20]. In 2006
we initiated the application of hfSRT whenever highly
focussed stereotactic intracranial radiotherapy was indicated
but tumour size or localization rendered a single-time
treatment impossible.
HfSRT of more than one metastasis was carried out
either simultaneously or successively in a primary setting
or in a recurrent situation. The aim of this retrospective
analysis was to evaluate an efficient and safe dose
concept of hfSRT for limited (1–4) brain metastases.Methods
Patient characteristics
Between April 2006 and December 2010, 75 patients with
108 brain metastases were treated with hfSRT and retro-
spectively analysed. After interdisciplinary discussion a
surgical treatment approach had been excluded due to
comorbidity, age, or localization of the tumour. Diagnosis
of brain metastases was based on pre-treatment magnetic
resonance imaging (MRI). Only patients with KarnofskyTable 1 Patients characteristics
Age Median (years), range
Gender male
female









Extracranial tumour status in remission
detectable, stable diseas
progressive




Time between diagnosis of primary tumour
and brain metastasis
Median (months), range
Time between diagnosis of brain metastasis
and start of hfSRT
Median (month), range
Intervall between WBRT and start of hfSRT Median (month), rangeperformance status ≥70 were included. 41 patients (55%)
received a primary definitive hfSRT of 52 newly diagnosed
metastases (48%). 34 patients (45%) with 56 metastases
(52%) were treated with hfSRT in a recurrence situation.
Patient and treatment characteristics are summarized in
Table 1 and 2.
The need of ethical approval is waived because of the
retrospective character of the study. Authorization for
the use of patient data was given to the authors by
the Head of the Departement of Radiooncology of the
Medical School in Hannover.Radiotherapy
All patients were informed about radiotherapeutic alterna-
tives, in detail. If hfSRT was chosen, repeated MRI scans
were conducted after completing radiotherapy, in order to
detect early intracranial progress or radiotoxicity. All
patients were immobilized using a tight thermoplastic
stereotactic head mask. Helical-CT images of 2 mm slice
thickness were fused with axial T1 weighted contrast
enhanced MR images. Gross Tumour Volume (GTV) wasTotal patients n=75
Primary n=41 Recurrence n=34
57.3 40.2-79.2 57.7 38.4-79.9
n [%] n [%]
20 48.8 15 44.1
21 51.2 19 55.9
er 22 53.6 11 32.4
5 12.2 12 35.3
6 14.6 3 8.8
4 9.8 2 5.9
0 0 5 14.7
4 9.8 1 2.9
7 17.1 13 38.2
34 82.9 21 61.8
0 0 0 0
5 12.2 11 32.4
e 10 24.4 8 23.5
26 63.4 15 44.1
32 78.0 19 55.9
7 17.1 9 26.5
2 4.9 5 14.7
0 0 1 2.9
12.5 0-166.4 12.3 0-337.7
1.4 0.2-39.9 11.4 0.5-37.9
0 0 12.7 0.5-28.8
Table 2 Treatment characteristics
Total metastases (108) Primary Range Recurrence Range
m=52 m=56
GTV Median (ccm) 1.0 0.1-19.0 2.0 0.1-29.2
PTV Median (ccm) 4.7 1.1-41.0 9.2 1.6-62.4
Brain volume treated with 4 Gy (V4Gy) Median (ccm) 18.4 0-55.3 16.6 0-68.7
Duration of hfSRT Median (days) 15 8-32 16 5-23
Recurrence situation WBRT dose concepts [%]
- 10x3 Gy 0 27 48.2
- 15x2.5 Gy 0 11 19.7
- 15x2 Gy 0 4 7.1
- 20x2 Gy 0 8 14.3
- others 0 6 10.7
m [%] m [%]
Localization of brain metastases frontal/frontoparietal 15 28.8 13 23.2
temporal 1 1.9 6 10.7
parietal/occipital 13 25.0 15 26.8
central brain 7 13.5 7 12.5
brainstem 3 5.8 2 3.6
cerebellum 8 15.4 11 19.6
others 5 9.6 2 3.6
Dose concepts EQD2 (Gy) median GTV (ccm)
10x3 Gy 33 9.29 1 1.9 3 5.4
5x4 Gy 23 4.00 0.0 3 5.4
7x4 Gy 33 4.70 0.0 11 19.6
8x4 Gy 37 2.75 2 3.8 4 7.1
9x4 Gy 42 5.56 0.0 2 3.6
10x4 Gy 47 4.50 7 13.5 2 3.6
4x5 Gy 25 4.00 0.0 1 1.8
5x5 Gy 31 2.00 0.0 5 8.9
6x5 Gy 38 1.00 10 19.2 14 25.0
7x5 Gy 44 0.87 22 42.3 4 7.1
5x6 Gy 40 0.76 10 19.2 7 12.5
total 1.46 52 100.0 56 100.0
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http://www.biomedcentral.com/1471-2407/12/497defined as the contrast enhancing tumour, a 4 mm margin
in all directions was added for definition of Planning Tar-
get Volume (PTV). Oncentra Masterplan Planning System
(Nucleotron, Germany, 84 lesions) or the Brainlab iPlan
System (Feldkirchen, 24 lesions) was used.
The chosen fractionation scheme depended on the
size, number and site of the brain metastases as well
as on the ‘re-irradiation’ factor in a recurrent situation.
Single doses of 5 to 6 Gy were aimed in primary setting,
single lesions, small GTV (< 2 ccm) and in uncritical
regions. If normal brain volume receiving more than
4 Gy (V4Gy) exceeded 23 ccm, the single dose was
reduced to 4 Gy to prevent toxicity [17]. For recurrence,generally a more restrictive fractionation concept
(Equivalent dose in 2 Gy fractions (EQD2 < 40 Gy) was
used. Dose concepts and associated mean GTV are sum-
marized in Table 2.
The EQD2 makes different radiation schedules com-
parable and is calculated with the equation EQD2 = D ×
([d + α/β]/[2 Gy + α/β]), considering the linear-quadratic
model. D is the total dose, d is the dose per fraction and
the α/β ratio is an experimentally defined value of tis-
sues. Assuming an α/β ratio of 10 Gy for tumour cell kill,
the EQD2 of the radiation concepts are 40 Gy (30 Gy
in 5 fractions), 44 Gy (35 Gy in 7 fractions) and 47 Gy
(40 Gy in 10 fractions), exemplarily (Table 2) [21].
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aging (IGRT) before irradiation by using a cone-beam
CT (XVI, Elekta) and X-ray images (Iview, Elekta) for
verification of the isocenter. Radiotherapy was carried
out using a Linac with 6 MVX photons in four to six
beams, and a multi leaf collimator with a leaf width of
1cm. For 24 lesions Brain Lab System with individual
blends was used.
Between each fraction at least one day treatment inter-
ruption was provided.Follow-up
Patients were monitored on a regular basis by the treat-
ing radiation oncologist. Performance status, neuro-
logical symptoms, and steroid uptake were monitored.
After a planned period of 6 to 12 weeks the first MRI
control was performed. Further follow-up MRI scans
were carried out in intervals of 2–3 months. Treatment
failure was considered as occurrence of new or increased
contrast enhancement in the irradiated area (with or
without increased volumes). Early side effects, i.e. alope-
cia, fatigue or headache, were scored with the CTC-AE
3.0 scoring system. Late effects (> 90 days after hfSRT)
were not considered as these could not be analysed sys-
tematically due to retrospective data collection.Overall 
survival
Months
Figure 1 Actuarial OS probability according to GTV calculated
by Kaplan-Meier (log-rank test; p< 0.019). GTV < 2 ccm (m=57):
continuous line, GTV ≥ 2 ccm (m=51): dotted line.Statistical analysis
Analysed endpoints were local control (LC), distant
brain control (DC), intracranial control (IC) and overall
survival (OS). Local relapse was defined as occurrence of
new or increasing contrast enhancement in follow-up
MRI in the irradiation area, after involvement of an
experienced neuroradiologist. Distant brain failure was
defined as any new brain metastases beyond local re-
lapse, intracranial failure as any intracranial progress in-
cluding local relapse. Survival rates and univariate
analysis were calculated by the Kaplan-Meier log-rank
test. All events were measured from the first treatment
day of hfSRT. The following variables were used: sex,
age (<57.5y. vs. ≥57.5y.), primary (non-small cell lung
cancer vs. other), RPA (recursive partitioning analysis)
prognostic group (1 vs. 2), primary vs. recurrent treat-
ment, GTV (<2.0 vs. ≥2.0 ccm), steroid uptake (yes
or no), median V4Gy (<16.7 ccm vs. ≥16.7 ccm), EQD2
(≤35 Gy vs. >35 Gy), median EQD2 (<39 Gy vs. ≥39 Gy),
median time interval between diagnosis of the primary
tumour and brain metastases (<12.5 vs. ≥12.5 months).
Multivariate Cox Proportional Regression Analysis was
performed only with variables significant in the univariate
analysis.
T-test of independent samples was used to compare
GTV of different dose concepts and to compare toxicity
rates. All statistical analysis was performed using IBMSPSS Statistics 20. A p-value <0.05 was considered to be
statistically significant.
Results
Overall survival and influencing factors
Median OS summed up to 9.1 months with a median
follow-up of 9.5 months (range 1.0-50.6 months). Median
follow-up of patients being alive until August 2012
(n=5,7%) was 36.6 months (range 21.9-50.6 months).
Actuarial 6- and 12-months-OS was 59% and 35%.
Variables with significant influence on OS after multi-
variate analysis were the extracranial activity of primary
tumour (p<0.001), the steroid uptake (p=0.03), the GTV
(p=0.019) (Figure 1) and a total dose EQD2≥39 Gy
(p=0.012). Detailed OS data is presented in Table 3.
Local and intracranial control
After a median of 2.2 months (range: 0.3-10.5 months)
patients received the first follow-up MRI scan. Two
patients (2.7%) were lost to follow-up and fourteen
patients (18.7%) died within 90 days (range 13–75 days)
of hfSRT and before the first follow-up imaging was car-
ried out. 88 lesions (81.5%) were evaluated.
Imaging was done in 56 cases within 40–90 days after
the end of hfSRT. 29 metastases (51.8%) showed a
complete remission, 20 (35.7%) a partiell remission and
7 (12.5%) a progress.
Local control in the irradiated area after 6 and 12
months was 73% and 52%, respectively, median LC was
11.9 months. The EQD2 significantly influenced LC
(p=0.004, multivariate analysis). Median LC was 14.9
months for EQD2 >35 Gy and 3.4 months for doses
≤35 Gy. Actuarial LC rates for biological irradiation
Table 3 Actuarial overall survival according to potential factors and the result of univariate and multivariate analysis









male 55 35 9.9
female 53 33 9.1
Age 0.777
< 57.5 years (median) 54 44 9.9
≥ 57.5 years (median) 54 24 6.3
NSCLC vs. Others 0.778
NSCLC 43 40 7.2
others 65 32 10.7
RPA 0.010
I 36 50 11.8
II 72 28 4.7
Extracerebral activity of primary tumor 0.001 0.001
not detectable 30 47 11.7
stable 25 48 10.0
progredient 53 23 4.0
Objective of therapy 0.217
primary 52 37 8.9
recurrence 56 34 10.0
Steroid uptake 0.005 0.030
yes 51 18 5.4
no 57 51 13.0
GTV 0.004 0.019
< 2 ccm 57 49 11.5
≥ 2 ccm 51 20 5.4
EQD2 (35 Gy) 0.021 0.298
≤ 35 Gy 24 13 3.6
> 35 Gy 84 42 10.7
EQD2 (median 39 Gy) 0.009 0.012
< 39 Gy 54 26 7.2
≥ 39 Gy 54 44 11.5
V4 Gy (median 16.7 ccm) 0.271
< 16.7 ccm 56 32 7.2
≥ 16.7 ccm 52 38 9.1
Time between diagnosis of primary and diagnosis of brain metastases 0.092
< 12.5 months 52 30 9.1
≥ 12.5 months 56 40 8.9
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57%/22% after 12 months, respectively (Figure 2). The
median EQD2 of < and ≥39 Gy was not a significant fac-
tor influencing LC.
LC analysis of different dose concepts showed a 6- and
12-months LC of 90%/66% for the 6x5 Gy concept. LC
for 5x6 Gy was 83%/63%, 73%/42% for 7x5 Gy and 64%/21% for 10x4 Gy, respectively. Differences in LC were
not significant.
Distant brain control (outside the irradiated area) after
6 and 12 months was 51% and 35%, median DC was 3.9
months. Fifteen patients with primary treated metastases
suffered from a distant brain relapse, four had multiple




Figure 2 Actuarial LC probability according to EQD2 calculated
by Kaplan-Meier (log-rank test; p=0.004). EQD2 > 35 Gy (m=73):
continuous line, EQD2 ≤ 35 Gy (m=15): dotted line.
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treated with hfSRT, nine with WBRT, one got further
chemotherapy and one had a surgical resection. Treat-
ment of two patients was not known.
Intracranial control (includes local and distant brain
control) was 41% and 20%, median being 3.4 months.
No other variables with significant influence on DC, IC,
LC and OS could be identified.Survival data of recurrence hfSRT
In recurrent situations 56 metastases were treated with a
median EQD2 of 38 Gy while in comparison 52 metasta-
ses in primary situation were treated with a median
EQD2 of 44 Gy.
The aspect of primary or recurrence hfSRT did not
have a statistically significant influence on OS or on
LC. Median OS of primary hfSRT was 8.8 months,
while in recurrence situations it was 10 months
(p=0.217 in univariate and p=0.124 in multivariate Cox
regression analysis). 6- and 12-months-OS-rates for
primary hfSRT were 62%/37% and for recurrence
hfSRT they were 57%/34%. 6- and 12-months-rates of
LC, DC and IC for primary hfSRT were 75%/55%,
56%/51% and 46%/30% while for recurrence hfSRT they
amounted 71%/49%, 46%/25% and 38%/16%, respectively.Toxicity
For proper interpretation of toxicity results, we would
like to point out, that 36 (48.0%) patients were treated
with chemotherapy during the 3-month time period be-
fore the start of hfSRT. Furhtermore, it should be con-
sidered that 40 patients (53.3%) received steroids duringradiotherapy. The median dose of dexamethasone at the
end of radiotherapy was 4 mg per day.
Only mild early toxicity (CTC-AE v. 3.0 grade 1) was
observed: alopecia (9 patients), fatigue (8 patients),
headache (6 patients), nausea (2 patients) or mucositis
(2 patients). One patient with hfSRT to four brain me-
tastases, treated with a molecular therapy (Sunitinib)
until the start of radiation, showed short term memory
loss and amnesic aphasia. Another patient with chemo-
therapy just until the start of hfSRT suffered from vision
disorder.
In only 2 cases out of 24 with a radiation dose EQD2
≤35 Gy (8.3%) a toxicity was seen compared to 26 cases
out of 84 with an EQD2 >35 Gy (31%, p=0.026).
The GTV (< and ≥2 ccm) and the a brain volume
treated with 4 Gy (V4Gy) (< and ≥ median of 16.7 ccm
or < and ≥ 23 ccm) had no significant influence on
toxicity (29.8% vs. 21.6%, p=0.328; 30.4% vs. 21.2%,
p=0.275; 31.2% vs. 17.1%, p=0.149).
One case of radiation necrosis was discussed in the
follow-up analysis. This patient with small cell lung car-
cinoma was initially treated with a prophylactic WBRT
with 30 Gy (15x2 Gy). After 14 months the MRI showed
3 metastases of the brain, each of them was treated with
hfSRT, the cerebellar metastasis was treated with a total
dose of 40 Gy (10x4 Gy, EQD2 = 47 Gy). This resulted
in a cumulative dose of 77 Gy in the cerebellum. The
suspicion of necrosis was raised after a progress of the
cerebellar metastasis with additional calcification show-
ing 6 months later. Simultaneously, the patient suffered
from cephalgia, emesis, vertigo and motor dysfunction.
She died 3 months later after implantation of an Omaya
reservoir and subsequent treatment with chemotherapy
and steroids.
Discussion
This study retrospectively analyses therapeutic results
in 75 patients treated with hfSRT to limited brain me-
tastases in a primary, or recurrence, situation. Since
2006 we are offering this option to patients who suffer
from limited brain metastases and where surgery or
SRS is not a suitable treatment option. We applied dif-
ferent dose concepts dependent on primary or recur-
rence situation, localization and volume of brain lesion.
Dose concepts with a total EQD2 >35 Gy achieved best
local control rates with acceptable toxicity. 12-months
LC rates of 52% are lower in comparison to other
hfSRT studies or SRS probably because we used very
different dose concepts [16,22-27].
The aim of our study was to find the most suitable
regime with respect to disease control and side effects.
Fahrig et al. also compared different dose concepts like
5x6-7 Gy, 7x5 Gy and 10x4 Gy and achieved 12 months
OS of 43%, 60% and 67%, respectively [28]. They
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size and localization of the metastases, and detected no
adverse side effects. However, a trend towards higher
rates of complete remission in patients with brain me-
tastases was seen treated with 5x6–7 Gy or 7x5 Gy in
comparison with 10x4 Gy [28]. We preferred using re-
strictive dose concepts (EQD2 < 40 Gy) in patients with
prior WBRT as well as in patients with high tumour
volume or tumour proxicity to critical structures.
The median EQD2 for GTV < 2 ccm was 40 Gy and
for GTV ≥ 2 ccm 38 Gy. The GTV was significantly
higher for metastases treated with a single dose of
3–4 Gy (median 4.76 ccm) than with 5–6 Gy (median
1.00 ccm, p < 0.001). Recent studies yielded LC rates
of 58.6% after 12 months in mean volumes of 8 ccm
(24 Gy in 3 fractions) [22] and 76% in median
volumes of 4.23 ccm (5x6 Gy after prior WBRT,
otherwise 5x7 Gy) [17]. Aoyama et al. found a signifi-
cant lower tumour control rate for tumours >3 ccm (35 Gy
in 4 fractions) [29]. Nevertheless, above mentioned hfSRT
studies included volumes higher than 3 ccm and showed
good results.
Conclusions can be drawn from our study results
only to a limited extent because of the relatively small
number of patients included, it being a mono-
institutional series and the potential risk of selection
biases due to the retrospective study design. However,
we consider the results to be valuable with regard to
the objective of our analysis. Conclusions of our ana-
lysis are also limited due to high diversity of dose con-
cepts (Table 2). In our study only 48% could be
classified into dose concepts defined by Fahrig et al.
[28]. Therefore, we could not see significant difference
for a specific dose concept for LC or OS.
Furthermore, we detected a significant influence of the
EQD2 (p = 0.004) on LC (14.9 months for doses >35 Gy
and 3.4 months for doses ≤ 35 Gy) in this study.
An EQD2 >35 Gy is associated with better control
rates along with higher but acceptable toxcitiy. There-
fore, we consider it is most effective for tumour control.
In SRS higher absolute doses (24 Gy) are associated
with higher LC (85%) after 12 months (compared to 45-
49% with 15–18 Gy) [30]. For brain metastases ≤2 ccm
SRS studies found that a single time 20 Gy application
seems to render superior results [31,32].
Rades et al. achieved higher LC rates with upfront
WBRT (77%) than with SRS alone (49%), and thereby
showed a benefit of up-front WBRT [33].
Half of our patients (45%) were treated in a recurrence
situation after prior WBRT. LC was not significantly dif-
ferent (49% after 12 months) in comparison to patients
who received primary treatment (55% after 12 months).
Lindvall et al. combined WBRT and hfSRT (30 Gy in 10
fractions and 17 Gy in 1–3 fractions) in 11 patients andcompared them to 44 patients with hfSRT (40 Gy in 5
fractions) alone. They showed high LC rates of 100%
and 84% in a short observation time (mean 3.7 months)
[19].
Nevertheless, GTV significantly influenced OS in our
study (< 2 ccm median 11.5 months ≥2 ccm median 5.4
months). Ernst-Stecken et al. defined GTV and PTV vol-
ume above 6 ccm and 13 ccm as negative prognostic fac-
tor for OS [17].
According to the results of Ernst-Stecken et al. brain
volume receiving >4 Gy per fraction should not exceed
23 ccm [17]. Takening this into account, overall adverse
effects were only mild in our study. None of our patients
suffered from seizures classified as a higher grade side
effect. In contrast, 11% of patients suffered of seizures
within 3 months after SRS [23].
A recurrence situation after WBRT or hfSRT has not
shown a statistically significant influence on LC, IC or
OS in our and other studies [22]. Overall survival for
hfSRT in primary and recurrence situations was median
8.8 months and 10 months, respectively. The actuarial
OS of 35% one year after treatment with hfSRT is com-
parable to the reported SRS series (30-50%) [16,23,25-
27] and hfSRT studies (25%) [22]. Different studies com-
pared SRS alone with WBRT plus a SRS boost. The
omission of WBRT in the initial management of patients
who underwent SRS alone did not compromise survival
or intracranial control [24,27,34,35]. De Potter et al. [36]
achieved a DC at 1 year of 75%. They used 5x6 Gy as a
boost in addition to WBRT. Patients with primary hfSRT
treatment in our study achieved a DC of only 51% after
one year and 60% of them had a WBRT as salvage ther-
apy. Similar DC results of 36% without up-front WBRT
were presented by Narayana et al. [37].
Therefore, up-front WBRT is worth discussing and not
simply expendable to avoid neurotoxicity of the normal
brain tissue. Regular MR imaging is necessary to detect
cerebral progress as soon as possible. Patients with lim-
ited brain metastases should be clearly informed about
all possible advantages and disadvantages of the different
therapy options.Conclusion
HfSRT to limited brain metastases is a non invasive
therapy in primary and recurrence situations, and pro-
vides a reasonable tumour control and survival benefit.
A total EQD2 >35 Gy is associated with better tumour
control rates and with higher but acceptable toxcitiy.
Therefore, it is most effective for control of limited brain
metastases.Competing interests
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